<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01076686</url>
  </required_header>
  <id_info>
    <org_study_id>SKY0402-C-318</org_study_id>
    <nct_id>NCT01076686</nct_id>
  </id_info>
  <brief_title>Observational Study to Assess Long-Term Follow-Up of Breast Augmentation Subjects</brief_title>
  <official_title>An Observational Study to Assess the Long-Term Follow-Up of Subjects Who Had Participated in SKY0402 Breast Augmentation Studies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pacira Pharmaceuticals, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pacira Pharmaceuticals, Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A history and physical focused on clinical sequelae of breast implant rupture was completed
      by patients to assess long-term clinical sequelae of SKY0402 and its relation to the silicon
      shell.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This was an observational, multicenter study conducted to investigate the long term follow-up
      of subjects who had been exposed to study drug (either SKY0402, bupivacaine HCl, or both) in
      prior SKY0402 breast augmentation studies. Specifically, the protocol was designed to elicit
      any changes in the response of the silicone shell of the implant after exposure to study
      drug.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2010</start_date>
  <completion_date type="Actual">March 2010</completion_date>
  <primary_completion_date type="Actual">March 2010</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Subjects With Breast Implant Rupture</measure>
    <time_frame>12 to 24 months post surgery</time_frame>
    <description>Breast implant rupture and integrity were assessed by reviewing the results of history and physical focused on clinical sequelae of augmentation mammoplasty</description>
  </primary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Actual">94</enrollment>
  <condition>Postoperative Pain</condition>
  <arm_group>
    <arm_group_label>Bupivacaine and low dose SKY0402</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Bupivacaine and high dose SKY0402</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Bupivacaine</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>High dose SKY0402</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Questionnaire and Physical Exam</intervention_name>
    <description>A 10-question survey and a six-item physical exam were completed.</description>
    <arm_group_label>Bupivacaine and low dose SKY0402</arm_group_label>
    <arm_group_label>Bupivacaine and high dose SKY0402</arm_group_label>
    <arm_group_label>Bupivacaine</arm_group_label>
    <arm_group_label>High dose SKY0402</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        All patients who had been exposed to study drug and had undergone breast augmentation.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participated in either Pacira SKY0402-C-210 or Pacira SIMPLE Breast Augmentation 315
             and received a dose of SKY0402, bupivacaine HCl, or both

          -  Able and willing to comply with all study visits and procedures.

          -  Able to speak, read, and understand the language of the informed consent, and any
             other instruments used for collecting subject-reported outcomes, in order to enable
             accurate and appropriate responses to study assessments.

          -  Able and willing to provide written informed consent

        Exclusion Criteria:

          -  Did not receive study drug in either Pacira SKY0402-C-210 or SIMPLE Breast
             Augmentation 315.

          -  Has a clinically significant systemic or psychiatric disease that may pose a
             significant safety risk or diminish a subject's ability to undergo all study
             procedures and assessments.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>December 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 25, 2010</study_first_submitted>
  <study_first_submitted_qc>February 25, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 26, 2010</study_first_posted>
  <results_first_submitted>November 6, 2011</results_first_submitted>
  <results_first_submitted_qc>April 15, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 14, 2012</results_first_posted>
  <last_update_submitted>April 15, 2012</last_update_submitted>
  <last_update_submitted_qc>April 15, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 14, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Augmentation mammoplasty</keyword>
  <keyword>Breast augmentation</keyword>
  <keyword>Postoperative pain</keyword>
  <keyword>Analgesia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bupivacaine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Bupivacaine and Low Dose SKY0402</title>
          <description>Single dose of study drug was injected locally into the breast pockets</description>
        </group>
        <group group_id="P2">
          <title>Bupivacaine and High Dose SKY0402</title>
          <description>Single dose of study drug was injected locally into the breast pockets</description>
        </group>
        <group group_id="P3">
          <title>Bupivacaine</title>
          <description>Single dose of study drug was injected locally into the breast pockets</description>
        </group>
        <group group_id="P4">
          <title>High Dose SKY0402</title>
          <description>Single dose of study drug was injected locally into the breast pockets</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="14"/>
                <participants group_id="P3" count="32"/>
                <participants group_id="P4" count="31"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="14"/>
                <participants group_id="P3" count="32"/>
                <participants group_id="P4" count="31"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Bupivacaine and Low Dose SKY0402</title>
          <description>Single dose of study drug was injected locally into the breast pockets</description>
        </group>
        <group group_id="B2">
          <title>Bupivacaine and High Dose SKY0402</title>
          <description>Single dose of study drug was injected locally into the breast pockets</description>
        </group>
        <group group_id="B3">
          <title>Bupivacaine</title>
          <description>Single dose of study drug was injected locally into the breast pockets</description>
        </group>
        <group group_id="B4">
          <title>High Dose SKY0402</title>
          <description>Single dose of study drug was injected locally into the breast pockets</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="17"/>
            <count group_id="B2" value="14"/>
            <count group_id="B3" value="32"/>
            <count group_id="B4" value="31"/>
            <count group_id="B5" value="94"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="32"/>
                    <measurement group_id="B4" value="31"/>
                    <measurement group_id="B5" value="94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32" spread="7.2"/>
                    <measurement group_id="B2" value="29" spread="6.3"/>
                    <measurement group_id="B3" value="31" spread="7.1"/>
                    <measurement group_id="B4" value="33" spread="7.6"/>
                    <measurement group_id="B5" value="32" spread="7.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="32"/>
                    <measurement group_id="B4" value="31"/>
                    <measurement group_id="B5" value="94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="32"/>
                    <measurement group_id="B4" value="31"/>
                    <measurement group_id="B5" value="94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects With Breast Implant Rupture</title>
        <description>Breast implant rupture and integrity were assessed by reviewing the results of history and physical focused on clinical sequelae of augmentation mammoplasty</description>
        <time_frame>12 to 24 months post surgery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Bupivacaine and Low Dose SKY0402</title>
            <description>Single dose of study drug was injected locally into the breast pockets</description>
          </group>
          <group group_id="O2">
            <title>Bupivacaine and High Dose SKY0402</title>
            <description>Single dose of study drug was injected locally into the breast pockets</description>
          </group>
          <group group_id="O3">
            <title>Bupivacaine</title>
            <description>Single dose of study drug was injected locally into the breast pockets</description>
          </group>
          <group group_id="O4">
            <title>High Dose SKY0402</title>
            <description>Single dose of study drug was injected locally into the breast pockets</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Breast Implant Rupture</title>
          <description>Breast implant rupture and integrity were assessed by reviewing the results of history and physical focused on clinical sequelae of augmentation mammoplasty</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="32"/>
                <count group_id="O4" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>30 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Bupivacaine and Low Dose SKY0402</title>
          <description>Single dose of study drug was injected locally into the breast pockets</description>
        </group>
        <group group_id="E2">
          <title>Bupivacaine and High Dose SKY0402</title>
          <description>Single dose of study drug was injected locally into the breast pockets</description>
        </group>
        <group group_id="E3">
          <title>Bupivacaine</title>
          <description>Single dose of study drug was injected locally into the breast pockets</description>
        </group>
        <group group_id="E4">
          <title>High Dose SKY0402</title>
          <description>Single dose of study drug was injected locally into the breast pockets</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Executive Medical Director</name_or_title>
      <organization>Pacira Pharmaceuticals</organization>
      <phone>203-837-6500</phone>
      <email>erolo@pacira.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

